Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

Stonepine Capital Management LLC raised its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 252.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,994 shares of the company’s stock after buying an additional 161,832 shares during the quarter. Xilio Therapeutics comprises 1.2% of Stonepine Capital Management LLC’s portfolio, making the stock its 24th biggest holding. Stonepine Capital Management LLC owned approximately 3.43% of Xilio Therapeutics worth $2,165,023,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Xilio Therapeutics during the 2nd quarter valued at approximately $84,000. State Street Corp increased its position in Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares during the last quarter. Jane Street Group LLC purchased a new stake in Xilio Therapeutics during the fourth quarter valued at $27,000. Squarepoint Ops LLC raised its stake in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after purchasing an additional 93,338 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after purchasing an additional 139,716 shares during the last quarter. Institutional investors own 54.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on XLO. Weiss Ratings cut shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Xilio Therapeutics presently has a consensus rating of “Sell”.

Xilio Therapeutics Stock Performance

Shares of Xilio Therapeutics stock opened at $9.01 on Friday. The stock has a market cap of $59.29 million, a price-to-earnings ratio of -5.49 and a beta of -0.14. The stock has a 50 day moving average price of $9.09 and a 200-day moving average price of $8.42. Xilio Therapeutics, Inc. has a one year low of $6.47 and a one year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.26. The company had revenue of $18.69 million for the quarter, compared to analyst estimates of $12.72 million. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.